Home World News Peptide Receptor Radionuclide Therapy Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive,... World News Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs By Ogkologos - July 28, 2026 177 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPETE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle July 20, 2021 Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... November 29, 2021 The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... December 20, 2018 Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 Load more HOT NEWS Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected... EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan Cancer in My Community: Caring for Children With Cancer in Paraguay Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality...
